◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › E › EXEL

Exelixis Inc (EXEL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Exelixis Inc (EXEL) operates in the BIOTECHNOLOGY industry and is headquartered in Alameda, United States with about 1,077 employees. Its market capitalization is roughly $14 billion. In the fiscal year ended 2025-12-31, EXEL reported $2.3B in revenue and $783M in net income.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Interactive charts & full statements → Open the EXEL valuation workbench →

EXEL Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$2.4B	$2.3B	$2.2B	$1.8B	$1.6B	$1.4B	$988M	$968M	$854M	$452M	$191M	$37M	$25M	$31M	$47M	$290M	$185M	$152M	$118M	$113M	$99M
Gross Profit	$2.4B	$2.2B	$2.1B	$1.8B	$1.6B	$1.4B	$951M	$935M	$827M	$437M	$185M	$33M	$23M	$30M	$47M	$290M	$185M	$152M	$118M	$113M	$98M
Gross Margin %	96.4%	96.4%	96.5%	96.0%	96.4%	96.3%	96.3%	96.6%	96.9%	96.7%	96.6%	89.5%	91.9%	96.4%	100.0%	100.0%	100.0%	100.0%	100.0%	99.8%	99.2%
Operating Income (EBIT)	$971M	$872M	$605M	$171M	$201M	$287M	$110M	$369M	$439M	$166M	($28M)	($121M)	($224M)	($201M)	($122M)	$90M	($91M)	($122M)	($179M)	($157M)	($127M)
Operating Margin %	39.8%	37.6%	27.9%	9.3%	12.5%	20.0%	11.1%	38.2%	51.4%	36.7%	-14.7%	-326.7%	-893.9%	-640.5%	-258.0%	30.9%	-49.4%	-80.3%	-152.1%	-138.4%	-128.5%
Net Income	$861M	$783M	$521M	$208M	$182M	$231M	$112M	$321M	$690M	$154M	($70M)	($170M)	($269M)	($245M)	($148M)	$76M	($92M)	($135M)	($163M)	($86M)	($101M)
Net Margin %	35.3%	33.7%	24.0%	11.3%	11.3%	16.1%	11.3%	33.2%	80.8%	34.1%	-36.7%	-456.6%	-1069.4%	-781.0%	-311.2%	26.1%	-49.9%	-89.1%	-138.2%	-76.1%	-102.9%
EBITDA	—	$922M	$719M	$283M	$222M	$300M	$119M	$378M	$452M	$167M	($22M)	($120M)	($213M)	($196M)	($115M)	$100M	($73M)	($116M)	($156M)	($157M)	($110M)
Earnings Per Share (EPS)	$3.17	$2.78	$1.76	$0.65	$0.56	$0.72	$0.35	$1.02	$2.21	$0.49	$-0.28	$-0.81	$-1.38	$-1.33	$-0.92	$0.58	$-0.85	$-1.26	$-1.54	$-0.87	$-1.17
Shares Outstanding (M)	—	282M	296M	321M	325M	322M	318M	315M	313M	312M	251M	209M	194M	184M	160M	130M	109M	107M	105M	99M	87M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EXEL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$629M	$611M	$599M	$598M	$568M	$555M	$567M	$540M	$637M
Gross Profit	$608M	$591M	$572M	$579M	$549M	$536M	$547M	$522M	$620M
Gross Margin %	96.7%	96.7%	95.6%	96.9%	96.6%	96.5%	96.5%	96.8%	97.2%
Operating Income (EBIT)	$248M	$251M	$235M	$237M	$214M	$187M	$163M	$136M	$276M
Operating Margin %	39.4%	41.1%	39.3%	39.6%	37.6%	33.6%	28.8%	25.2%	43.3%
Net Income	$212M	$210M	$245M	$194M	$185M	$160M	$140M	$118M	$226M
Net Margin %	33.7%	34.5%	40.8%	32.4%	32.5%	28.7%	24.7%	21.9%	35.5%
EBITDA	—	$275M	$243M	$260M	$238M	$213M	$171M	$195M	$284M
Earnings Per Share (EPS)	$0.82	$0.79	$0.87	$0.69	$0.65	$0.55	$0.50	$0.40	$0.77
Shares Outstanding (M)	—	267M	282M	279M	284M	288M	282M	291M	294M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EXEL Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$1.2B	$884M	$700M	$333M	$363M	$401M	$209M	$527M	$416M	$166M	$206M	($142M)	($235M)	($199M)	($123M)	($159M)	($101M)	($15M)	($10M)	($69M)	($45M)
Capital Expenditures (CapEx)	$13M	$40M	$66M	$163M	$138M	$64M	$30M	$13M	$33M	$21M	$2M	$0M	$0M	$2M	$3M	$1M	$2M	$6M	$15M	$17M	$12M
Free Cash Flow (FCF)	$1.2B	$844M	$634M	$170M	$224M	$337M	$179M	$514M	$382M	$144M	$205M	($142M)	($236M)	($201M)	($126M)	($160M)	($103M)	($20M)	($25M)	($86M)	($57M)
FCF Margin %	48.0%	36.4%	29.2%	9.3%	13.9%	23.5%	18.1%	53.1%	44.8%	31.9%	106.9%	-382.1%	-939.3%	-641.2%	-265.2%	-55.3%	-55.6%	-13.5%	-21.1%	-75.9%	-57.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EXEL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$308M	$252M	$334M	$290M	$49M	$211M	$240M	$271M	$120M
Capital Expenditures (CapEx)	$9M	$2M	$1M	$1M	$4M	$22M	$14M	$9M	$25M
Free Cash Flow (FCF)	$298M	$250M	$332M	$289M	$45M	$189M	$226M	$262M	$95M
FCF Margin %	47.4%	40.9%	55.5%	48.3%	8.0%	34.0%	39.9%	48.6%	14.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EXEL Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$2.5B	$2.8B	$2.9B	$2.9B	$3.1B	$2.6B	$2.1B	$1.9B	$1.4B	$655M	$598M	$332M	$328M	$503M	$721M	$393M	$361M	$343M	$402M	$412M	$395M
Cash & Cash Equivalents	$281M	$482M	$217M	$263M	$501M	$647M	$319M	$267M	$315M	$183M	$152M	$142M	$80M	$104M	$170M	$74M	$97M	$87M	$248M	$135M	$123M
Total Liabilities	$650M	$683M	$703M	$678M	$583M	$406M	$258M	$200M	$135M	$370M	$508M	$437M	$443M	$437M	$425M	$303M	$589M	$507M	$458M	$327M	$305M
Total Debt (Short + Long-Term)	—	$0M	$25M	$26M	$18M	$9M	$3M	$3M	$69M	$58M	$189M	$799M	$362M	$347M	$336M	$182M	$208M	$80M	$118M	$122M	$122M
Total Shareholders' Equity	$1.8B	$2.2B	$2.2B	$2.3B	$2.5B	$2.2B	$1.9B	$1.7B	$1.3B	$285M	$89M	($104M)	($115M)	$66M	$296M	$91M	($228M)	($164M)	($57M)	$72M	$53M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EXEL viewer.

EXEL Metric Deep Dives

Other Companies in BIOTECHNOLOGY

BNTX · BioNTech SE — $24 billion
GMAB · Genmab AS — $21 billion
JAZZ · Jazz Pharmaceuticals PLC — $16 billion
ASND · Ascendis Pharma AS — $16 billion
SMMT · Summit Therapeutics PLC — $14 billion
BBIO · BridgeBio Pharma Inc — $13 billion
HALO · Halozyme Therapeutics Inc — $13 billion
BMRN · Biomarin Pharmaceutical Inc — $12 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← EXE All “E” companies EXENS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.